Research Paper

Principles and Practices of IT Enables Management

Sun Pharmaceuticals

By: Hardik Saini

16030141081

MBA (IT) Div. B

SICSR

Company: Sun pharmaceuticals Industries Limited

Founded: 1983

Founder: Mr.Dilip Shanghavi

Headquarters: Mumbai, Maharashtra.

Total Revenue: ₹26,628 Crores (2015)

No. of Employees: 52,700 in over 50 Nationalities.

Share Price: BSE 801.80

NSE 800.55

Introduction Sun Pharma is the fifth largest speciality generic pharmaceutical

company in the world.

It was founded in 1983 by Dilip Shanghvi and its head offices are in

Mumbai.

At present, its Chairman is Israel Makov and Dilip Shanghvi operates

as the Managing Director.

Apart from pharmaceuticals, it deals in generic drugs.

In the 2013-14 fiscal, it earned revenue of US$ 2.6 billion and its

operating income was US$ 1.1 billion.

In the same period, its net income was US$ 900 million and the

aggregate worth of its assets was US$ 2.2 billion. In the 2013-14

fiscal, its total equity stood at US$ 4.7 billion.

Sun Pharmaceuticals was set up in 1983 and the company started off with

only 5 products to cure psychiatric illness. Sun Pharma is best known

worldwide as the manufacture of specialty Active Pharmaceuticals

Ingredients and formulations.

However, the company is also concerned with chronic treatments such as

cardiology, psychiatry, neurology, gastroenterology, diabetology, and

respiratory ailments. Active Pharmaceuticals Ingredients (API) include

peptides, steroids, hormones, and anti-cancer drugs and their quality is

internationally approved.

The international offices of Sun Pharmaceuticals Industries Ltd. are located

in British Virgin Islands, Russia, and Bangladesh. In India, the offices are in

Vapi, Silvassa, Panoli, Ahmednagar, and Chennai. Dilip S. Shanghvi is the

Executive Chairman and managing Director of Sun Pharma and Kamalesh

H. Shah is the secretary.

There are 3 major group companies of Sun Pharmaceuticals Industries are:

Caraco Pharmaceuticals Laboratories (based in Detroit, Michigan)

Sun Pharmaceuticals Industries Inc. (Michigan)

Sun Pharmaceuticals (Bangladesh).

In 1994, Sun Pharma enrolled itself in the main stock exchanges in India.

Subsequently in 1995, the first API manufacturing plant was established at

Panoli to mark its standard beyond competition and also capture the

international market.

Latest Financial Figures(Figures in Rs. Crores)

ET 500 Rank (2011)127

Turnover 5859.98

Profit after Tax(PAT) 1816.06

Market Capitalization 49698.44

Assets 10756.05

Management

Name Designation

Dilip S Shanghvi Managing Director

Sailesh T Desai Whole Time Director

Hasmukh S Shah Director

Ashwin Dani Director

Israel Makov Chairman

Sudhir V Valia Whole Time Director

S Mohanchand Dadha Director

Keki M Mistry Director

Rekha Sethi Director

Sun pharma has ensured world-class quality in design, equipment

and operations in all their manufacturing facilities across the world.

They have 48 ( API & finished dose) state-of-the-art manufacturing

sites spanning 5 continents.

These manufacturing units are located in India, the US, Brazil,

Canada, Hungary, Israel, Bangladesh, Mexico, Romania, Ireland,

Morocco, Nigeria, South Africa and Malaysia.

They provide best-in-class products to patients across 150 countries

worldwide.

45+ Manufacturing Sites 150+ Markets Served 2000+ Marketed Products 50,000+ Employees Worldwide

Functions

Medical research and development

Production

Sales

Marketing

Quality Assurance

HR

Business Development

Head Employees

CHIEF FINANCIAL OFFICER

Uday V. Baldota (w.e.f. August 12, 2014)

COMPANY SECRETARY

Sunil R. Ajmera

AUDITORS

Deloitte Haskins & Sells Chartered Accountants, Mumbai.

CORPORATE HR

Jyoti Shivastava

QUALITY HEAD

Bhushan Rajput

NATIONAL SALES HEAD

Mahendra Varman

HEAD ADMINISTRATION AND SECURITY

Umesh Pradhan

HEAD MERGER AND ACQUISITIONS

Arvind Kumar

DIRECTOR (SALES & TRADE MARKETING)

Anindya Chaudhary

HEAD ERP

Ghanshyam Naik

STRATEGY & BUSINESS DEVELOPMENT LEAD

Brain Mulnix

Head of Corporate Quality Policies, Training, and Communications

James Carrol

Regional Head of Quality

Daniel Martin